Dulaglutide
Dulaglutide (Trulicity)
Table of Contents
What is Dulaglutide?
Dulaglutide (brand name Trulicity) is a GLP-1 receptor agonist manufactured by Eli Lilly, approved for treatment of type 2 diabetes and reduction of cardiovascular risk. It was one of the first once-weekly GLP-1 agonists available, reaching the market in 2014, predating semaglutide by several years.
The molecule is a fusion protein: a GLP-1 analog (similar to natural GLP-1 but modified for stability) attached to a modified human IgG4 Fc region. This large fusion protein is protected from degradation and cleared slowly from the body, resulting in a half-life of approximately 5 days—long enough for once-weekly dosing.
Dulaglutide works through the same mechanism as other GLP-1 agonists: activating GLP-1 receptors to stimulate insulin secretion (when glucose is high), suppress glucagon, slow gastric emptying, and reduce appetite through brain effects. The result is improved blood sugar control and typically some weight loss.
While semaglutide has become the dominant GLP-1 agonist due to superior weight loss in clinical trials, dulaglutide remains widely used with an excellent safety record from years of clinical experience and robust cardiovascular outcome data from the REWIND trial.
Research Benefits
FDA-approved for type 2 diabetes
Once-weekly dosing convenience
Proven cardiovascular risk reduction (REWIND trial)
Significant HbA1c reduction
Moderate weight loss effects
Pre-filled injection pen (easy to use)
Extensive real-world safety data
Does not require refrigeration after first use
How Dulaglutide Works
Dulaglutide activates GLP-1 receptors throughout the body, producing multiple effects that improve metabolic function.
Glucose-Dependent Insulin Secretion
When blood glucose rises, GLP-1 receptor activation enhances insulin release from pancreatic beta cells. This effect is glucose-dependent—insulin increases only when needed, reducing hypoglycemia risk compared to medications that stimulate insulin release regardless of glucose levels.
Glucagon Suppression
Dulaglutide suppresses glucagon release from pancreatic alpha cells. Since glucagon raises blood sugar by stimulating liver glucose production, this suppression helps lower blood glucose.
Gastric Emptying
GLP-1 receptor activation slows gastric emptying, prolonging fullness after meals and reducing post-meal glucose spikes.
Central Appetite Effects
GLP-1 receptors in the brain mediate appetite suppression and satiety. This central effect drives the weight loss seen with GLP-1 agonists, though it's more modest with dulaglutide than with semaglutide.
Research Applications
Type 2 diabetes management
Active research area with published studies
Cardiovascular disease prevention
Active research area with published studies
Weight management (secondary)
Active research area with published studies
Pre-diabetes intervention
Active research area with published studies
Metabolic syndrome
Active research area with published studies
Chronic kidney disease with T2D
Active research area with published studies
GLP-1 receptor pharmacology
Active research area with published studies
Research Findings
Dulaglutide has extensive clinical trial data from its development program (AWARD trials) and cardiovascular outcomes trial (REWIND).
AWARD Program
The AWARD trials compared dulaglutide to various active comparators. Results showed significant HbA1c reductions (typically 0.8-1.5%) and modest weight loss (2-4 kg on average). Dulaglutide was non-inferior or superior to comparators including metformin, insulin glargine, and exenatide.
REWIND Trial
The REWIND cardiovascular outcomes trial followed 9,901 patients for a median of 5.4 years. Results showed:
- 12% reduction in major adverse cardiovascular events
- Benefits in patients with and without established cardiovascular disease
- Significant reductions in all-cause mortality trends
This established dulaglutide as cardioprotective in a broad diabetic population.
Comparison to Semaglutide
The SUSTAIN 7 trial directly compared semaglutide and dulaglutide, finding semaglutide superior for both HbA1c reduction and weight loss at all dose comparisons. This head-to-head data positioned semaglutide as the more efficacious option, though dulaglutide remains effective.
Dosage & Administration
Dulaglutide is administered as a once-weekly subcutaneous injection using pre-filled pens.
Available Doses
- 0.75mg (starting dose)
- 1.5mg (standard maintenance)
- 3.0mg (higher dose option)
- 4.5mg (maximum dose)
Typical Titration
- Start: 0.75mg weekly for 4 weeks
- Increase to 1.5mg weekly
- May increase to 3.0mg then 4.5mg if needed for glycemic control
Administration
Inject subcutaneously in abdomen, thigh, or upper arm. Same day each week; can adjust day if needed. The pre-filled pen is designed for easy self-administration and doesn't require refrigeration after first use.
Safety & Side Effects
Dulaglutide's safety profile is well-characterized from clinical trials and years of post-marketing experience.
Common Side Effects
- Nausea (most common, often improves)
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
Boxed Warning
Like all GLP-1 agonists, dulaglutide carries a warning about thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2.
Other Considerations
- Pancreatitis risk (monitor for symptoms)
- Hypoglycemia when combined with insulin/sulfonylureas
- Possible gallbladder effects